Jupiter Neurosciences, Inc. Common Stock (JUNS) - Total Assets
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) holds total assets worth $5.56 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Jupiter Neurosciences, Inc. Common Stock to assess the company's total reinvestment commitment from operating cash flow.
Jupiter Neurosciences, Inc. Common Stock - Total Assets Trend (2019–2025)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Check Jupiter Neurosciences, Inc. Common Stock (JUNS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Jupiter Neurosciences, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Jupiter Neurosciences, Inc. Common Stock's total assets of $5.56 Million consist of 86.7% current assets and 13.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.1% |
| Accounts Receivable | $2.64K | 0.1% |
| Inventory | $159.79K | 2.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Jupiter Neurosciences, Inc. Common Stock.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jupiter Neurosciences, Inc. Common Stock's current assets represent 86.7% of total assets in 2025, an increase from 80.4% in 2019.
- Cash Position: Cash and equivalents constituted 68.1% of total assets in 2025, up from 20.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 2.9% of total assets.
Jupiter Neurosciences, Inc. Common Stock Competitors by Total Assets
Key competitors of Jupiter Neurosciences, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Jupiter Neurosciences, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 1.91 | 0.13 |
| Quick Ratio | 0.63 | 1.91 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.57 Million | $1.72 Million | $-3.71 Million |
Jupiter Neurosciences, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Jupiter Neurosciences, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 227.66 |
| Latest Market Cap to Assets Ratio | 1.50 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | $5.56 Million |
| Market Capitalization | $8.33 Million USD |
Valuation Analysis
Above Book Valuation: The market values Jupiter Neurosciences, Inc. Common Stock's assets above their book value (1.50x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Jupiter Neurosciences, Inc. Common Stock's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
The table below shows the annual total assets of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.56 Million | -10.29% |
| 2024-12-31 | $6.20 Million | +4074.12% |
| 2023-12-31 | $148.59K | -37.02% |
| 2022-12-31 | $235.94K | -64.65% |
| 2021-12-31 | $667.38K | +21.35% |
| 2020-12-31 | $549.98K | +8803.72% |
| 2019-12-31 | $6.18K | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinic… Read more